Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo matching Dapagliflozin, Thiazolidinedione (Pioglitazone); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 972 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 57
States / cities: Anniston, Alabama • Ozark, Alabama • Phoenix, Arizona + 51 more

Conditions: Chronic Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: n-3 polyunsaturated fatty acids, Placebo; Dietary Supplement · Other
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Agawam, Massachusetts

Conditions: Refractory Chronic Cough
Interventions: 5 mg Serlopitant Tablets, Matching Placebo Tablets; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 29
States / cities: Los Angeles, California • Mission Viejo, California • San Diego, California + 24 more

Conditions: Moderate Risk of CVD
Interventions: Aspirin (Acetylsalicylic acid, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 55 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 73
States / cities: Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more

Conditions: Asthma
Interventions: Placebo, Benralizumab 25 mg, Benralizumab 100 mg, Benralizumab 200 mg; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Encinitas, California • Los Angeles, California • Colorado Springs, Colorado + 3 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 124
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: palbociclib, Cetuximab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 14
States / cities: La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more

Conditions: CKD Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Tempe, Arizona • Alhambra, California + 48 more

Conditions: Antibody-Mediated Rejection (AMR)
Interventions: Mezagitamab, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 10 more

Conditions: Tuberculosis
Interventions: MK-7762 (TBD09), Placebo; Drug · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 19 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Osteoarthritis
Interventions: GLPG1972, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 932 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 38 more

Conditions: COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions: Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more

Conditions: Acute Pain
Interventions: Tapentadol oral solution 4 mg/mL, Tapentadol oral solution 20 mg/mL, Placebo; Drug · Other
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Little Rock, Arkansas • Stanford, California • Miami, Florida + 9 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab, Placebo; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 25 Years
Enrollment: 723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 34
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 29 more

Conditions: Immune Senescence, Sarcopenia
Interventions: Oral PS-IPC supplement, Placebo supplement; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 60 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Crohn's Disease
Interventions: Placebo matching with BMS-945429, BMS-945429; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: La Jolla, California • San Diego, California • Lone Tree, Colorado + 5 more

Conditions: Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
Interventions: ASC30 tablets A1, Placebo; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 84
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more

Conditions: Asthma
Interventions: tiotropium-bromide, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more

Conditions: Low Back Pain, Low Back Pain, Recurrent
Interventions: JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg, JNJ-42160443 10 mg, Matching Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Multiple Sclerosis
Interventions: Polyphenon E, Placebo; Drug · Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Alzheimer's Disease
Interventions: Rosiglitazone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 862 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more

Conditions: HIV, Endothelial Dysfunction, Oxidative Stress
Interventions: PharmaNAC (N-acetylcysteine), Matching placebo; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Add-on to Thiazolidinedione (TZD) Failures

Study of Efficacy of Ramelteon in Adults With Chronic Insomnia

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults